Company Profile: Revvity, Inc. (RVTY)

RVTY insider trades (13 months) →

$163.48 +7.84% vs. previous close · Market cap $18.24B

Today's multi-factor rank: 156 of 461 · see the ranking

Quant500 Scores

Momentum

7.4/10

Value

4.4/10

Growth

4.3/10

Quality

4.5/10

Multifactor

5.1/10

Market and Valuation

Price & Market

Prev Close Price:$151.60

Open:$163.01

Day's Low:$162.58

Day's High:$171.74

Bid / Ask:-

Market Cap:18.24B

Enterprise Value:19.24B

52-Week Range

52-Week Low:$81.22

52-Week High:$171.74

Current position in 52-week range

52w Low-52w High

50-Day Avg:$145.02

200-Day Avg:$112.06

Volume

Volume Today:3,372,215

Avg Volume (3m):1,859,187

Avg Volume (10d):1,861,190

52-Week Change:+65.34%

vs S&P 500, 52 weeks:-

Beta:1.09

Valuation Multiples

P/E (trailing):78.22

Diluted EPS for the last 12 months: the four quarters ended Jul 5, 2026, from the accounts filed with the SEC on Aug 11, 2026. The P/E is the price divided by that EPS.

P/E (forward):27.73

PEG Ratio:0.73

Price / Book:2.52

Price / Sales (TTM):6.26

EV / Revenue:6.61

EV / EBITDA:21.96

Dividends

Current yield:0.18%

Annual Dividend Rate:$0.28

Dividend Trailing:$0.28

Yield Trailing:0.18%

5-Year Avg Yield:0.23%

Payout Ratio:13.40%

Last Ex-Dividend Date:-

Valuation Context

P/E vs sector (indicative)

Most Recent Quarter:-

Fiscal Year (Next):-

Date Filter (Month):

Loading historical OHLCV database...

Financial Statements TTM (Trailing 12 Months)

Income Statement

Total Revenue (TTM):2.91B

Gross Profit:1.60B

EBITDA:875.83M

Net Income (TTM):237.37M

Rev Growth (YoY):+1.30%

Earnings Growth (YoY):+1.20%

Quarterly earnings growth (YoY):-3.90%

Margins

Gross Margin:-

EBITDA Margin:-

Operating Margin:-

Net Margin:-

Per Share

EPS Trailing (TTM):$2.09

Diluted EPS for the last 12 months: the four quarters ended Jul 5, 2026, from the accounts filed with the SEC on Aug 11, 2026. The P/E is the price divided by that EPS.

EPS Forward (Est.):$5.89

Revenue Per Share:$25.77

Cash Per Share:-

Book Value:$64.78

Last Dividend:-

Ex-Dividend Date:-

Last Split:-

Balance Sheet & Liquidity

Total cash:1.02B

Total Debt:3.34B

Net Debt (Debt - Cash):2.32B

Debt / Equity:46.23%

Current Ratio:1.80

Quick Ratio:1.36

Cash Flows

Operating Cash Flow:627.63M

Free Cash Flow (FCF):604.99M

FCF Yield (FCF / Market Cap):-

Enterprise Value:19.24B

EV / Revenue:6.61

EV / EBITDA:21.96

Profitability

ROE (Return on Equity):3.21%

ROA (Return on Assets):2.37%

P/E (trailing):78.22

P/E (forward):27.73

Price / Book:2.52

PEG Ratio:0.73

52-Week Change:+65.34%

S&P 500 change, 52 weeks:+11.37%

Historical Evolution (Last 4 Years)

Income Statement

Balance Sheet

Cash Flow

EPS and Earnings Per Share

Key EPS Metrics

EPS Trailing (TTM):$2.09

Diluted EPS for the last 12 months: the four quarters ended Jul 5, 2026, from the accounts filed with the SEC on Aug 11, 2026. The P/E is the price divided by that EPS.

EPS Forward (Est.):$5.89

P/E (forward):27.73

PEG Ratio:0.73

Growth and Margins

Earnings Growth YoY:-

Quarterly Earnings Growth YoY:-

Rev Growth YoY:-

Net Margin:-

Gross Margin:-

EBITDA Margin:-

Per Share

Revenue Per Share:$25.77

Cash Per Share:-

Book Value:$64.78

Cash Flows (TTM)

Free Cash Flow:604.99M

Operating Cash Flow:627.63M

EBITDA:875.83M

Total Revenue (TTM):2.91B

Net Income (TTM):237.37M

Fiscal Year (Last):-

EPS Surprise History - Last 4 Quarters

Actual vs. Analyst Estimates · Green = beat expectations · Red = missed

Quarter	Period	Actual EPS	Estimated EPS	Difference	Surprise %	Currency

Ownership Structure

Ownership Distribution

% Insiders:-

% Institutional:-

% Inst. (of Float):-

No. of Institutions:-

Visual distribution

InsidersInstitutionalFree Float

Shares & Short Interest

Shares Outstanding:111,586,401

Float (free shares):102,492,109

Short interest (shares):6,391,660

Short % of float:-

Short Ratio (days to cover):2.82

Short interest, prior month:-

Short Interest Date:-

Governance Score (1=Best, 10=Worst)

Overall risk:-

Audit Risk:-

Board risk:-

Compensation Risk:-

Shareholder rights risk:-

Top Institutional Holders

Position Change: ▲ Increased · ▼ Reduced · = Unchanged

Organization	Report Date	% Shares	No. Shares	Value (USD)	Change %

Top Mutual Funds

Position Change: ▲ Increased ▼ Decreased = Unchanged

Fund	Report Date	% Shares	No. Shares	Value (USD)	Change %

Recent Insider Trades

Executive / Insider	Title	Date	Action	Shares

Options Chain

Expiration Date:

CALLS

Strike	Last	Bid	Ask	Vol.	O.I.	IV

PUTS

Strike	Last	Bid	Ask	Vol.	O.I.	IV

Revvity, Inc. (RVTY) SEC filings: 10-K, 10-Q and 8-K

Direct links to financial reports filed with the SEC.

Type	Date	Official link
10-Q	2026-08-11	View filing ↗
8-K	2026-08-04	View filing ↗
11-K	2026-06-23	View filing ↗
SD	2026-06-01	View filing ↗
10-Q	2026-05-12	View filing ↗
8-K	2026-05-05	View filing ↗
8-K	2026-05-01	View filing ↗
DEF 14A	2026-03-16	View filing ↗
PRE 14A	2026-03-06	View filing ↗
10-K	2026-02-24	View filing ↗

Company and Executive Profile

Revvity, Inc. provides health sciences solutions, technologies, and services. The company offers instruments, reagents, software, subscriptions, detection and imaging technologies, extended warranties, and training and services; and instruments, reagents, and assay platforms and software products for early detection of common and rare conditions, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. It also develops technologies that enable and support genomic workflows using protein coupled receptors and next-generation DNA sequencing for oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies under the AutoDELFIA, chemagic, Chitas, CNGnome, DELFIA, DELFIA Xpress, EONIS, EUROArray, EUROIMMUN, EUROLabWorkstation, EUROLINE, EUROPattern, Evolution Evoya, GSP, Haoyuan, IDS Immunodiagnosticsystems, IDS-i10, IDS-i10T, IDS-i20, IDS-iSYS, iLab, iQ, LifeCycle, LimsLink, Migele, NeoBase, NeoLSD, NEXTFLEX, Panthera Puncher, PreNAT II, Prime, RONIA, SimplicityChrom, Specimen Gate, Superflex, Symbio, T-SPOT, Vanadis, ViaCord, VICTOR2, and WholePanel brand names, as well as under the Accell, AlphaLISA, AlphaPlex, AlphaScreen, Alpha SureFire, AssayMate, BIOCHIPs, BioLegend, Bioo Scientific, BioQule, Brilliant Violet, Ce3D, CellCarrier, Cellaca, Celigo, Cellometer, cell::explorer, Cell-Vive, Chalice, ChemDraw, CHOSOURCE, Dharmacon, and DharmaFECT brand names. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.

General Information

Headquarters:United States

City:Waltham

Employees:11,000

Sector:Healthcare

Industry:Diagnostics & Research

Website:-

Key Executives

Name	Title	Age	Total pay
Dr. Prahlad R. Singh Ph.D.	CEO, President & Director	60	3.56M
Mr. Maxwell Krakowiak	Senior VP & CFO	35	1.18M
Mr. Tajinder S. Vohra	Senior Vice President of Global Operations	59	1.03M
Mr. Joel S. Goldberg	Senior VP of Administration, General Counsel & Secretary	56	1.25M
Ms. Miriame Victor	Senior Vice President & Chief Business Officer	44	1.04M
Ms. Anita Gonzales	Chief Accounting Officer, VP & Controller	49	-
Mr. Bryan A. Kipp	Senior VP of Technology & Licensing	-	-
Dr. Madhuri Hegde FACMG, Ph.D.	Senior VP & Chief Scientific Officer	-	-

You have seen the engine room

A free account saves your simulator portfolios, your personal portfolio and your Academy progress, synced across devices. And, if you switch it on, the email alert the same day an insider buys stock in their own company.

No card. No spam.

Revvity, Inc. (RVTY): Quantitative Analysis

Name: Factor scores for Revvity, Inc. (RVTY)
Creator: Quant500
License: https://quant500.com/legal

Revvity, Inc. (RVTY) — Healthcare — Diagnostics & Research. RVTY is in the S&P 500 today. Model factor scores and market data, recalculated every trading day.

So far in 2026, RVTY has returned +69.3% against +11.4% for the S&P 500 (SPY): total return, dividends included on both sides, from Dec 31, 2025 to Nov 3, 2026.

RVTY ranks 156 of 461 on today's multifactor score, and 17 of the 55 Healthcare companies that score. Its strongest factor is momentum (Z 1.44, ranked 35 of 494); its weakest is growth (Z -0.44, ranked 399 of 489). Each factor ranks only the companies with data for it, and the multifactor score only those with all four: that is why the totals differ.

Factor scores

The Z-Score is how many standard deviations the company sits from the index average: 0 is average, positive is better than average, negative is worse.

Factor	Z-Score	Rank
Multifactor	0.076	156 of 461
Momentum	1.440	35 of 494 ↑2
Value	-0.375	320 of 489 ↓24
Quality	-0.317	328 of 468
Growth	-0.444	399 of 489

Market data

Metric	Value
Price	$163.48
Market Cap	18.24B
P/E	78.22
Revenue (last 12 months)	2.91B
Price / book	2.52
Book value per share	$64.78
52-week range	$81.22 – $171.74
Dividend yield	0.18%
Beta	1.09
Average volume	1,859,187
Shares outstanding	111.59M
Short interest (% of float)	8.58% (as of Oct 15, 2026)

When does RVTY report earnings? 12 of its last 12, before the open →

What are RVTY insiders doing? 53 transactions filed with the SEC, of them 11 sells, the last one on Oct 1, 2026 →

RVTY latest SEC filings

Annual report (10-K): filed Feb 24, 2026, fiscal year ended Dec 28, 2025 · view the filing on sec.gov
Quarterly report (10-Q): filed Aug 11, 2026, quarter ended Jul 5, 2026 · view the filing on sec.gov
Earnings release (8-K): Nov 3, 2026, before the open · view the 8-K on sec.gov

Filing dates on EDGAR, the SEC's public registry. All RVTY filings on EDGAR.

Guides: How to read a Quant500 company page · What the S&P 500 is · P/E ratio explained · 10-K, 10-Q and 8-K · all guides

Frequently asked questions about Revvity (RVTY)

When does Revvity report earnings?

Revvity has no announced date in the Nasdaq public calendar checked (Nov 3, 2026 to Dec 7, 2026). Of its last 12 earnings announcements: 12 before the open (SEC filings through Nov 3, 2026). RVTY earnings dates and times, quarter by quarter →

What is Revvity's P/E ratio?

Revvity's P/E (price over earnings per share for the last twelve months) is 78.2 at the Nov 3, 2026 close. That EPS is the 12-month diluted figure from the SEC, the four quarters ended Jul 5, 2026. The median of the 54 Healthcare companies with a P/E is 30.5, and the S&P 500's, 23.5: Revvity is above its sector median. Healthcare stocks, company by company →

Where does Revvity rank on Quant500?

In the Nov 3, 2026 multi-factor ranking, Revvity ranks 156 of 461, and 17 of the 55 Healthcare companies that score. The ranking orders S&P 500 companies by the average of four factors (momentum, value, quality and growth) and is recalculated every trading day. It is a model output, not investment advice. The full ranking → How it is calculated →

Have Revvity insiders bought or sold shares?

SEC Form 4 shows no open-market purchase of Revvity shares from August 2025 through Nov 3, 2026. The latest sale was on Oct 1, 2026, by an officer, for $13k. In total, from August 2025 through Nov 3, 2026: 0 purchases and 11 sales by directors, officers and large shareholders. All RVTY insider trades →

Does Revvity pay a dividend?

Yes. Its dividend yield is 0.18% at the Nov 3, 2026 close (annual dividend of $0.28 per share). The latest recorded ex-dividend date is Oct 23, 2026.

What sector is Revvity in, and which index?

Revvity is classified in the Healthcare sector (industry: Diagnostics & Research), per the data provider's classification (similar to GICS, not identical). It is in the S&P 500 today. It is one of the 59 S&P 500 companies in that sector. Healthcare stocks →

What is behind these numbers

The concepts on this page, explained from scratch in the Academy. Free, no account.

Valuation multiples: P/E, P/B, EV/EBITDA and their trapsWhy the P/E and the price-to-book in the table above cannot be compared across sectors, and what a low P/E can hide.
Value and momentum: the two that have survived bestWhat the value and momentum scores on this page actually measure, and why they are the two factors that have best survived scrutiny.
Quality and low volatilityWhere the quality score comes from, and why it is the factor with the most competing definitions, all of them called the same thing.
Sales growth: the driver that gets overestimated mostWhat sits behind the growth score and the twelve-month revenue, and why it is the number people extrapolate too far most often.
Dividends and payout: high is not always goodThis company pays a dividend and its yield is in the table above: when a high figure is good news and when it is a warning.

The whole Academy, course by course →

Data as of Nov 3, 2026. Source: point-in-time SEC fundamentals and closing prices. Method and formulas are on the home page.

Company Profile: Revvity, Inc. (RVTY)

Market and Valuation

Price & Market

52-Week Range

Volume

Valuation Multiples

Dividends

Valuation Context

Financial Statements TTM (Trailing 12 Months)

Income Statement

Margins

Per Share

Balance Sheet & Liquidity

Cash Flows

Profitability

Historical Evolution (Last 4 Years)

Income Statement

Balance Sheet

Cash Flow

EPS and Earnings Per Share

Key EPS Metrics

Growth and Margins

Per Share

Cash Flows (TTM)

EPS Surprise History - Last 4 Quarters

Ownership Structure

Ownership Distribution

Shares & Short Interest

Governance Score (1=Best, 10=Worst)

Top Institutional Holders

Top Mutual Funds

Recent Insider Trades

Options Chain

CALLS

PUTS

Sentiment Metrics

Expected move

Revvity, Inc. (RVTY) SEC filings: 10-K, 10-Q and 8-K

Company and Executive Profile

General Information

Key Executives

You have seen the engine room

Revvity, Inc. (RVTY): Quantitative Analysis

Factor scores

Market data

RVTY latest SEC filings

Frequently asked questions about Revvity (RVTY)

When does Revvity report earnings?

What is Revvity's P/E ratio?

Where does Revvity rank on Quant500?

Have Revvity insiders bought or sold shares?

Does Revvity pay a dividend?

What sector is Revvity in, and which index?

What is behind these numbers